Targeted conversion of the transthyretin gene in vitro and in vivo

Gene Therapy

Volumn 11, Issue 10, 2004, Pages 838-846

  Nakamura, M ^a   Ando, Y ^a   Nagahara, S ^b   Sano, A ^b   Ochiya, T ^c   Maeda, S ^d   Kawaji, T ^a   Ogawa, M ^a   Hirata, A ^a   Terazaki, H ^a   Haraoka, K ^a   Tanihara, H ^a   Ueda, M ^a   Uchino, M ^a   Yamamura, K ^e  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Atelocollagen; Familial amyloidotic polyneuropathy; Single stranded oligonucleotides; Targeted gene repair; Transthyretin

Indexed keywords

AMYLOID; ANTISENSE OLIGONUCLEOTIDE; ATELOCOLLAGEN; GENOMIC DNA; METHIONINE; PLASMID DNA; PREALBUMIN; VALINE;

ALLELE; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CHIMERAPLASTY; CONTROLLED STUDY; DNA REPAIR; FAMILIAL AMYLOID POLYNEUROPATHY; GENE AMPLIFICATION; GENE CONVERSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TRANSPLANTATION; MOUSE; MUTANT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

AMYLOID NEUROPATHIES; ANIMALS; BASE SEQUENCE; COLLAGEN; DNA REPAIR; GENE CONVERSION; GENE TARGETING; GENE THERAPY; HUMANS; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; PREALBUMIN; TRANSFECTION;

MURINAE; MUS MUSCULUS;

EID: 20244385523     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302228     Document Type: Article

References (44)

1. Araki S. Type I familial amyloidotic polyneuropathy (Japanese type). Brain Dev 1984; 6: 128-133.
2. Benson MD. Familial amyloidotic polyneuropathy. Trends Neurosci 1989; 12: 88-92.
3. Connors LH, Richardson AM Theberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 2000; 7: 54-69.
4. Holmgren G et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 113-116.
5. Ericzon BG, Holmgren G, Lundgren E, Suhr OB. New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umea, Sweden, June 1999. Amyloid 2000; 7: 145-147.
6. Skinner M et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994; 120: 133-134.
7. Takei Y et al. Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. Ann Intern Med 1999; 131: 592-595.
8. Ando Y et al. Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet 1995; 345: 195-196.
9. Suhr O et al. Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig Dis Sci 1996; 41: 1909-1914.
10. Lendoire J et al. Liver transplantation in transthyretin familial amyloid polyneuropathy: first report from Argentina. Amyloid 1996; 6: 297-300.
11. Yoon K, Cole-Strauss A, Kmiec EB. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA-DNA oligonucleotide. Proc Natl Acad Sci USA 1996; 93: 2071-2076.
12. Cole-Strauss A et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 1996; 273: 1386-1389.
13. Kren BT, Cole-Strauss A, Kmiec EB, Steer CJ. Targeted nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide. Hepatology 1997; 25: 1462-1468.
14. Xiang Y et al. Targeted gene conversion in a mammalian CD34+-enriched cell population using a chimeric RNA/DNA oligonucleotide. J Mol Med 1997; 75: 829-835.
15. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotide. Nat Med 1998; 4: 285-290.
16. Alexeev V, Yoon K. Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA/DNA oligonucleotide. Nat Biotechnol 1998; 16: 1343-1346.
17. Kren BT et al. Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type 1 with a chimeric oligonucleotide. Proc Natl Acad Sci USA 1999; 96: 10349-10354.
18. Gamper HB et al. A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry 2000; 39: 5808-5816.
19. Gamper HB et al. The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res 2000; 28: 4332-4339.
20. Liu L, Rice MC, Kmiec EB. In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides. Nucleic Acids Res 2001; 29: 4238-4250.
21. Maeda S et al. What lessons to learn from the rodent models carrying targeted mutations at the TTR locus?. In : Bernstein L and Ingenbleek Y (eds) First International congress on Transthyretin in Health and Disease. Université Louis Pasteur: Strasbourg, 2002, pp. 32 (Abstr. L. 10 ).
22. Tsuzuki T et al. Structure of human prealbumin gene. J Biol Chem 1985; 260: 12224-12227.
23. Wakasugi S, Maeda S, Shimada K. Structure and expression of the mouse prealbumin gene. J Biochem 1986; 100: 49-58.
24. Takeda S, Ichii S, Nakamura Y. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Hum Mutat 1993; 2: 112-117.
25. Estibeiro P, Godfray J. Antisense as a neuroscience tool and therapeutic agent. Trends Neurosci 2001; 24 (Suppl): S56-S62.
26. Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets 2001; 1: 177-196.
27. Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990; 29: 10695-10702.
28. Perez-Ruiz M, Barroso-deljesus A, Berzal-herranz A. Specificity of the hairpin ribozyme. J Biol Chem 1999; 274: 29376-29380.
29. Tanaka K et al. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 2001; 183: 79-84.
30. Ando Y et al. Down regulation of a harmful variant protein by replacement of its normal protein. Biochim Biophys Acta 1997; 1362: 39-46.
31. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
32. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861-870.
33. Fujioka K, Takada Y, Sato S, Miyata T. Novel delivery system for proteins using collagen as a carrier material: the minipellet. J Control Rel 1995; 33: 307-315.
34. Ochiya T et al. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the minipellet. Nat Med 1999; 5: 707-710.
35. Lee CH, Singla A, Lee Y. Biomedical applications of collagen. Int J Pharmacol 2001; 221: 1-22.
36. Bohling SD, King TC, Wittwer CT, Elenitoba-Johnson KS. Rapid simultaneous amplification and detection of the MBR/JH chromosomal translocation by fluorescence melting curve analysis. Am J Pathol 1999; 154: 97-103.
37. Nakao M, Janssen JW, Flohr T, Bartram CR. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology Cancer Res 2000; 60: 3281-3289.
38. Kren BT, Metz R, Kumar R, Steer CJ. Gene repair using chimeric RNA-DNA oligonucleotides. Semin Liver Dis 1999; 19: 93-104.
39. Richardson PD, Kren BT, Steer CJ. Gene repair in the new age of gene therapy. Hepatology 2002; 35: 512-518.
40. Tagalakis AD et al. Gene conversion of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty. J Biol Chem 2001; 276: 13226-13230.
41. Yamamura K et al. Tissue-specific and developmental expression of human transthyretin gene in transgenic mice. Dev Genet 1987; 8: 195-205.
42. Stenzel KH, Miyata T, Rubin AL. Collagen as a biomaterial. Annu Rev Biophys Bioeng 1974; 3: 231-253.
43. Honma K et al. Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions. Biochem Biophys Res Commun 2001; 289: 1075-1081.
44. Misumi S et al. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease. Biochem Biophys Res Commun 1997; 241: 275-280.